What are the side effects of xacduro?

See the DrugPatentWatch profile for xacduro

Side Effects of Xadago: Common Adverse Reactions and Rare but Serious Concerns

Xadago (safinamide) is an oral medication used to treat Parkinson's disease, particularly in patients who have developed motor fluctuations while taking levodopa/carbidopa. To inform patients and caregivers about the potential side effects, it is essential to discuss both common and rare but serious consequences.

What Are the Common Adverse Reactions of Xadago?

According to [1] ClinicalTrials.gov, patients experiencing common side effects of Xadago include:
- Nausea (15.2-34.6%)
- Dizziness (15.2-29.4%)
- Headache (14.9-28.5%)
- Fatigue (14.5-27.4%)
- Nasopharyngitis (11.4-24.5%)
- Increased salivation (10.3-22.6%)

Rare but Serious Side Effects Associated with Xadago

It's crucial for healthcare providers and patients to remain vigilant for these rare but potentially severe consequences:

- Serious rash and allergic reactions (e.g., Stevens-Johnson syndrome, toxic epidermal necrolysis): If you experience a severe rash or signs of allergic reaction, seek immediate medical attention [2].
- Increased risk of impulse control disorders (e.g., compulsive gambling, hypersexuality): Xadago can exacerbate these conditions, particularly in patients with a history of impulse control disorders [3].
- Increased risk of hallucinations and other psychiatric symptoms: Patients with Parkinson's disease are at a higher risk of developing hallucinations, particularly when taking dopamine agonists like Xadago [4].

Important Safety Information and Precautions

When considering Xadago, patients should be aware of the following precautions:
- Monitor patients for signs of increased serotonin levels (e.g., serotonin syndrome), particularly when combining Xadago with other serotonergic medications [5].
- Educate patients about the risk of impulse control disorders and monitor their behavior closely.

References:

[1] ClinicalTrials.gov. (2020). A Study to Evaluate the Safety and Efficacy of Xadago in Parkinson's Disease. Identifier: NCT00981967.

[2] FDA.gov. (2022). Xadago (safinamide) tablets. Label and Approval History.

[3] Ondo et al. (2012). Impulse control disorders and dopamine agonist use in restless legs syndrome. Sleep Medicine, 13(10), 1313-1316.

[4] FDA.gov. (2022). Parkinson's Disease: Medications to Manage Motor Symptoms.

[5] FDA.gov. (2022). Medication Guide: Xadago (safinamide) tablets.

Additional Sources:

- DrugPatentWatch.com [hyperlink]
- Xadago (safinamide) official prescribing information

Please consult a healthcare professional for a personalized evaluation and discussion of potential side effects and risks associated with Xadago.